Which dose of vandetanib works best for thyroid cancer?
NCT ID NCT01496313
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two daily doses (150mg vs 300mg) of the drug vandetanib in 81 adults with advanced medullary thyroid cancer that had spread or caused symptoms. The goal was to see which dose better shrinks tumors and how side effects compare. Patients took the drug for up to 24 months, with dose reductions allowed for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vandetanib
What this could lead to
If successful, this could help doctors choose the best dose of vandetanib to control advanced medullary thyroid cancer with fewer side effects.
What could go wrong
This is a small, completed Phase 4 study, so results may not apply to all patients. Vandetanib can cause serious side effects like heart problems and diarrhea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 1901
Prague, 15006, Czechia
-
Investigational Site Number : 1903
Olomouc, 77900, Czechia
-
Investigational Site Number : 5703
Gliwice, 44-101, Poland
-
Investigational Site Number : 5704
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Research Site
Houston, Texas, United States
-
Research Site
Olomouc, Czechia
-
Research Site
Prague, Czechia
-
Research Site
Bangalore Karnataka, India
-
Research Site
Vellore, India
-
Research Site
Beersheba, Israel
-
Research Site
Haifa, Israel
-
Research Site
Jerusalem, Israel
-
Research Site
Petah Tikva, Israel
-
Research Site
Catania, Italy
-
Research Site
Milan, Italy
-
Research Site
Palermo, Italy
-
Research Site
Pisa, Italy
-
Research Site
Roma, Italy
-
Research Site
Siena, Italy
-
Research Site
Torino, Italy
-
Research Site
Groningen, Netherlands
-
Research Site
Leiden, Netherlands
-
Research Site
Gliwice, Poland
-
Research Site
Warsaw, Poland
-
Research Site
Zgierz, Poland
-
Research Site
Saint Petersburg, Russia
-
Research Site
Cardiff, United Kingdom
-
Research Site
Greater London, United Kingdom
-
Research Site
London, United Kingdom
-
Research Site
Tyne & Wear, United Kingdom